Humacyte, Inc. Warrant

Humacyte, Inc. announced the appointment of two prominent nephrologists, Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury, as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. The appointments follow positive Phase 3 V012 study results in women and plans to file a supplemental B...

Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology company, announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, generating $50 million in gross proceeds. The company plans to use the funds to commercialize Symvess®, file a Biologics License Application supplement for hemodialys...

Humacyte, Inc. (Nasdaq: HUMA) announced the pricing of an underwritten public offering of approximately 47.6 million shares at $1.05 per share, expected to raise $50 million in gross proceeds. The company plans to use the net proceeds to fund commercialization of Symvess®, advance pipeline development, and support general corporate purposes. The...

Humacyte, Inc. (Nasdaq: HUMA) announced an underwritten public offering of common stock with Barclays, BTIG, and Titan Partners as joint book-running managers. The company plans to use net proceeds to fund commercialization of Symvess®, file a supplemental BLA for hemodialysis indication, develop pipeline candidates, and support general corporat...

Humacyte announced Q1 2026 financial results showing Symvess product revenue of $0.5M (up from $0.1M in Q1 2025) with 29 units sold. The company appointed industry veterans James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer to accelerate commercialization. Key upcoming milestone includes Phase 3 hemodial...